Lupin Delays €190 Million VISUfarma Acquisition Timeline to February 2026
Lupin Limited has updated the timeline for its €190 million acquisition of Netherlands-based VISUfarma B.V., pushing the completion date from end-2025 to February 28, 2026. The transaction, being executed through wholly-owned subsidiary Nanomi B.V., will strengthen Lupin's European ophthalmology presence with VISUfarma's 60+ branded products and established market presence across major European countries.
*this image is generated using AI for illustrative purposes only.
Lupin Limited , a global pharmaceutical leader, has announced a significant move to strengthen its presence in the European ophthalmology market. The company's wholly-owned subsidiary, Nanomi B.V., has entered into a definitive agreement to acquire VISUfarma B.V., a Netherlands-based specialty pharmaceutical company, for an enterprise value of €190 million.
Revised Transaction Timeline
In a recent regulatory filing, Lupin has provided an update on the acquisition timeline. The company has informed stock exchanges that the proposed transaction, originally expected to be completed by the end of 2025, is currently in progress and is now expected to be completed by February 28, 2026, subject to certain closing conditions.
| Parameter: | Details |
|---|---|
| Original Timeline: | End of 2025 |
| Revised Timeline: | February 28, 2026 |
| Transaction Status: | In Progress |
| Enterprise Value: | €190 million |
Strategic Expansion into European Ophthalmology
The acquisition of VISUfarma aligns with Lupin's strategy to expand its European business and advance its global specialty franchise in ophthalmology. VISUfarma, founded in 2016, has established a strong presence across major European countries, including Italy, the UK, Spain, Germany, and France.
VISUfarma's Portfolio and Performance
VISUfarma offers a comprehensive portfolio of over 60 branded ophthalmology products, covering key areas such as dry eye treatments, glaucoma care, eyelid hygiene, blepharitis management, retinal health solutions, and specialized nutraceuticals.
| Year: | Revenue (€ million) |
|---|---|
| 2024: | 48.10 |
| 2023: | 42.50 |
| 2022: | 43.90 |
Regulatory Approvals and Current Status
The acquisition requires approval from national authorities for foreign direct investment in Germany and notification in Spain. Lupin will finance the acquisition through existing cash on its balance sheet. The transaction, valued at €190 million enterprise value, is expected to be accretive to Lupin's growth and margin profile.
Market Expansion Opportunities
This strategic move will provide Lupin with direct presence in major European markets, opportunities for business diversification, and a platform to accelerate expansion into the specialty ophthalmology segment across regions. The global ophthalmology market, currently valued at approximately €28 billion, is experiencing significant growth driven by an aging global population, increasing incidence of diabetes-related eye complications, and growing awareness of preventive care.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.59% | -2.05% | -9.95% | -17.23% | -1.50% | +106.99% |
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
